An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)

This study has been completed.
Sponsor:
Collaborator:
Shionogi
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01621191
First received: June 14, 2012
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.


Condition Intervention Phase
Fibromyalgia
Drug: Duloxetine
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Number of Participants Who Experienced an Adverse Event (AE) [ Time Frame: Baseline through 53 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Patient Global Impression-Improvement at Endpoint [ Time Frame: 50 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Impression-Improvement at Endpoint [ Time Frame: 50 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 50 Week Endpoint in Fibromyalgia Impact Questionnaire [ Time Frame: Baseline, 50 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 50 Week Endpoint in Brief Pain Inventory (BPI) Pain Severity Items and Interference Items of the BPI-Modified Short Form Score [ Time Frame: Baseline, 50 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 50 Week Endpoint in 36-Item Short-Form Health Survey [ Time Frame: Baseline, 50 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 50 Week Endpoint in Beck Depression Inventory-II [ Time Frame: Baseline, 50 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline to 50 Week Endpoint in Widespread Pain Index and Symptom Severity in American College of Rheumatology Fibromyalgia Diagnostic Criteria 2010 [ Time Frame: Baseline, 50 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: June 2012
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 60 mg Duloxetine
Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
Drug: Duloxetine
Administered Orally
Other Names:
  • LY248686
  • Cymbalta
  • Ariclaim
  • Xeristar
  • Yentreve

  Eligibility

Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants who have completed the 15-week treatment in the preceding study F1J-JE-HMGZ (NCT01552057)
  • Participants who wish continuous treatment with duloxetine after the preceding study
  • Participants are able to give their own written consent

Exclusion Criteria:

  • Participants with serious cardiovascular, hepatic, renal, respiratory, or hematological disease, or clinically significant laboratory or electrocardiogram abnormality which indicate a serious medical problem or require significant intervention in the judgment of the investigators
  • Participants with alanine aminotransferase/aspartate aminotransferase of not less than 100 International Unit/Liter (IU/L) or total bilirubin of not less than 1.6 milligram/deciliter (mg/dL) at week 0 (Visit 8 of the preceding study)
  • Participants with serum creatinine level of not less than 2.0 mg/dL, participant who has undergone kidney transplantation or hemodialysis at week 0 (Visit 8 of the preceding study)
  • Participants with pain difficult to discriminate from pain associated with fibromyalgia or disease which disturbs the assessment
  • Participants with thyroidal dysfunction, excluding those assessed by the investigator that the disorder is controlled as appropriate by three-month or longer drug therapy
  • Participants with present or past history of rheumatoid arthritis, inflammatory arthritis, infectious arthritis, or auto immune disease rather than thyroid deficiency
  • Participants with uncontrolled angle closure glaucoma
  • Participants who received a Monoamine oxidase (MAO) inhibitors within 14 days before week 0 (Visit 8 of the preceding study) or need to receive a MAO inhibitor within 5 days after study discontinuation
  • Participants who have experienced suicidal ideation or suicide attempt during the preceding study
  • Participants answering "yes" to any of the questions about active suicidal ideation/intent/behaviors occurring in the preceding study (Columbia Suicide Severity Rating Scale, Suicide Ideation section - Questions 4 and 5; Suicidal Behavior section)
  • Female participants who are pregnant, lactating, or who want to get pregnant during the study period. Male participants who want his partner to get pregnant
  • Females of child-bearing potential who can't agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study
  • Participants assessed ineligible by the investigator (sub-investigator) for other reasons
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01621191

Locations
Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Miyagi, Japan, 982-0032
Sponsors and Collaborators
Eli Lilly and Company
Shionogi
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01621191     History of Changes
Other Study ID Numbers: 14614, F1J-JE-HMHB
Study First Received: June 14, 2012
Last Updated: February 20, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare
Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Duloxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Adrenergic Agents
Dopamine Uptake Inhibitors
Dopamine Agents
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 22, 2014